NAD+ SupplementNMNWith Radioimmunotherapy in Advanced NSCLC
Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
This is a phase I, single center (West China Hospital, Sichuan University) study aimed at investigating the safety and efficacy of NMN supplements combined with chemotherapy and radiation therapy for second-line and above treatment of advanced NSCLC.